Long-term results of the FIN-RACo trial; treatment with a combination of traditional disease-modifying anti-rheumatic drugs is an excellent option in early rheumatoid arthritis

摘要: The Finnish Rheumatoid Arthritis Combination Therapy Trial (FIN-RACo) started in 1993, an era of disappointing results the treatment rheumatoid arthritis (RA). FIN-RACo was first trial aiming at remission and comparing two different strategies: initially triple therapy with compulsory prednisolone (FIN-RACo strategy), or monotherapy optional (SINGLE strategy). 2, 5 11 years are favour initial strategy without increase adversities. Nevertheless, targeted treatment, even SINGLE group patients show low disease activity moderate radiographic progression. Most leading rheumatologists participated have become convinced excellent results, good safety, feasible administration strategy. They thus adopted it real life tutored next generation to do same. This has undoubtedly affected approach treating early RA; Current Care Guideline recommends combination as choice early, active RA. As a consequence, use biologics RA is less frequent Finland compared many countries. Simultaneously, however, least one hard outcome RA, work disability, decreased.